Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
about
Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action.Facilitators and Barriers to Participation in PrEP HIV Prevention Trials Involving Transgender Male and Female Adolescents and Emerging Adults.HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have sex with men in 8 African countries: A cross-sectional analysis.Young Transgender Women's Attitudes Toward HIV Pre-exposure Prophylaxis.
P2860
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
@en
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
@nl
type
label
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
@en
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
@nl
prefLabel
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
@en
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
@nl
P2093
P2860
P921
P1476
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
@en
P2093
Daniel Reirden
Jose Castillo-Mancilla
Peter L Anderson
P2860
P304
P356
10.1097/QAI.0000000000001105
P407
P478
72 Suppl 3
P5008
P577
2016-08-01T00:00:00Z
2016-08-15T00:00:00Z